The relationship between physical activity and lymphoma: a systematic review and meta analysis.
Lymphoma
Meta-analysis
Physical activity
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
06 Oct 2020
06 Oct 2020
Historique:
received:
10
06
2020
accepted:
16
09
2020
entrez:
7
10
2020
pubmed:
8
10
2020
medline:
23
4
2021
Statut:
epublish
Résumé
The literature suggests an increased risk between anthropometrics including higher body mass index and lymphoma incidence; however, the association with physical activity remains unclear. A systematic review/meta-analysis was therefore performed to examine this association with physical activity (total, recreational or occupational). PubMed, Web of Science and Embase were reviewed from inception to October 2019 identifying relevant observational studies. Non-Hodgkin lymphoma (NHL) including subtypes diffuse large B cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma, and Hodgkin lymphoma (HL) were analyzed. Included studies reported activity, lymphoma cases, effect size and variability measures, and were restricted to human subjects of any age. Data was pooled generating summary relative risk (RR) estimates with 95% confidence intervals (CI) using random-effects models with primary outcome of histologically confirmed incident lymphoma. One thousand four hundred studies were initially identified with 18 studies (nine cohort, nine case-control) included in final analysis. Comparing highest vs. lowest activity categories was protective for all lymphoma (RR 0.89, 95%CI 0.81-0.98). Sensitivity analysis demonstrated effect persistence within case-control studies (RR 0.82, 95% CI 0.71-0.96), but not cohort studies (RR 0.95, 95%CI 0.84-1.07). Borderline protective effect was seen for NHL (RR 0.92, 95%CI 0.84-1.00), but not HL (RR 0.72, 95%CI 0.50-1.04). Analysis by NHL subtype or gender showed no effect. Dose response analysis demonstrated a protective effect (p = 0.034) with a 1% risk reduction per 3 MET hours/week (RR 0.99, 95%CI 0.98-1.00). Physical activity may have a protective effect against lymphoma development; further studies are required to generate recommendations regarding health policy. This study was registered prospectively at PROSPERO: CRD42020156242 .
Sections du résumé
BACKGROUND
BACKGROUND
The literature suggests an increased risk between anthropometrics including higher body mass index and lymphoma incidence; however, the association with physical activity remains unclear. A systematic review/meta-analysis was therefore performed to examine this association with physical activity (total, recreational or occupational).
METHODS
METHODS
PubMed, Web of Science and Embase were reviewed from inception to October 2019 identifying relevant observational studies. Non-Hodgkin lymphoma (NHL) including subtypes diffuse large B cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma, and Hodgkin lymphoma (HL) were analyzed. Included studies reported activity, lymphoma cases, effect size and variability measures, and were restricted to human subjects of any age. Data was pooled generating summary relative risk (RR) estimates with 95% confidence intervals (CI) using random-effects models with primary outcome of histologically confirmed incident lymphoma.
RESULTS
RESULTS
One thousand four hundred studies were initially identified with 18 studies (nine cohort, nine case-control) included in final analysis. Comparing highest vs. lowest activity categories was protective for all lymphoma (RR 0.89, 95%CI 0.81-0.98). Sensitivity analysis demonstrated effect persistence within case-control studies (RR 0.82, 95% CI 0.71-0.96), but not cohort studies (RR 0.95, 95%CI 0.84-1.07). Borderline protective effect was seen for NHL (RR 0.92, 95%CI 0.84-1.00), but not HL (RR 0.72, 95%CI 0.50-1.04). Analysis by NHL subtype or gender showed no effect. Dose response analysis demonstrated a protective effect (p = 0.034) with a 1% risk reduction per 3 MET hours/week (RR 0.99, 95%CI 0.98-1.00).
CONCLUSIONS
CONCLUSIONS
Physical activity may have a protective effect against lymphoma development; further studies are required to generate recommendations regarding health policy.
TRIAL REGISTRATION
BACKGROUND
This study was registered prospectively at PROSPERO: CRD42020156242 .
Identifiants
pubmed: 33023529
doi: 10.1186/s12885-020-07431-x
pii: 10.1186/s12885-020-07431-x
pmc: PMC7539461
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
962Références
J Musculoskelet Neuronal Interact. 2013 Jun;13(2):133-46
pubmed: 23728100
Eur J Epidemiol. 2015 May;30(5):397-412
pubmed: 25800123
Isr J Health Policy Res. 2016 Sep 22;5:40
pubmed: 27688873
Cancer Epidemiol. 2011 Apr;35(2):151-9
pubmed: 21030330
Int J Sports Med. 2000 Apr;21(3):216-20
pubmed: 10834356
Am J Epidemiol. 2009 Nov 15;170(10):1231-40
pubmed: 19822569
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):392-5
pubmed: 17337642
Cancer Epidemiol Biomarkers Prev. 2018 Aug;27(8):945-954
pubmed: 30026295
Med Sci Sports Exerc. 1999 Apr;31(4):566-71
pubmed: 10211853
Crit Rev Oncol Hematol. 2018 Sep;129:113-123
pubmed: 30097229
J Natl Cancer Inst Monogr. 2014 Aug;2014(48):98-105
pubmed: 25174030
Stat Med. 2010 Nov 20;29(26):2679-87
pubmed: 20809481
CMAJ. 2006 Mar 14;174(6):801-9
pubmed: 16534088
J Clin Oncol. 2016 Sep 1;34(25):2997-3004
pubmed: 27382104
Am J Public Health. 1991 May;81(5):639-42
pubmed: 2014869
Cancer Epidemiol. 2012 Feb;36(1):52-9
pubmed: 21816698
Epidemiology. 1993 May;4(3):218-28
pubmed: 8512986
J Natl Cancer Inst Monogr. 2014 Aug;2014(48):87-97
pubmed: 25174029
J Natl Cancer Inst Monogr. 2014 Aug;2014(48):130-44
pubmed: 25174034
Cancer Causes Control. 2005 Dec;16(10):1203-14
pubmed: 16215871
Leuk Res. 2018 Jun;69:7-11
pubmed: 29609041
Am J Epidemiol. 2002 Sep 15;156(6):527-35
pubmed: 12226000
Int J Cancer. 2019 Jul 15;145(2):347-359
pubmed: 30614529
Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):873-7
pubmed: 25934832
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Ann Oncol. 2013 May;24(5):1370-7
pubmed: 23247659
J Natl Cancer Inst. 2012 Oct 17;104(20):1548-61
pubmed: 22914790
Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1095-101
pubmed: 16775165
Ann Epidemiol. 2012 Dec;22(12):855-62
pubmed: 23146413
Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):833-46
pubmed: 24633143
J Cancer Epidemiol. 2012;2012:978930
pubmed: 23008714
Cancer Epidemiol Biomarkers Prev. 2013 Jul;22(7):1173-84
pubmed: 23677574
Oncologist. 2010;15(10):1083-101
pubmed: 20930095
Am J Epidemiol. 2005 Dec 15;162(12):1162-73
pubmed: 16269580
Leuk Lymphoma. 2006 Aug;47(8):1535-44
pubmed: 16966264
JAMA Intern Med. 2016 Jun 1;176(6):816-25
pubmed: 27183032
Methods Mol Biol. 2009;472:191-215
pubmed: 19107434
Menopause. 2017 Mar;24(3):322-344
pubmed: 27779567
Curr Oncol Rep. 2012 Dec;14(6):550-8
pubmed: 22945451
Clin J Sport Med. 2016 Nov;26(6):445-464
pubmed: 27347864
Am J Epidemiol. 2007 Sep 15;166(6):697-708
pubmed: 17596266
Eur J Cancer. 2011 Mar;47(5):748-60
pubmed: 21159506
Int J Cancer. 2012 Oct 15;131(8):1912-20
pubmed: 22275172
J Natl Cancer Inst Monogr. 2014 Aug;2014(48):26-40
pubmed: 25174024
Cancer Epidemiol Biomarkers Prev. 2012 Jun;21(6):905-15
pubmed: 22499775